Skip to content

Bictegravir

Bictegravir (Biktarvy) is an antiretroviral ingredient used in combination with other medicines to treat HIV-1 infection. This listing covers the one formulation of bictegravir available in the catalogue.

Biktarvy

Human Immunodeficiency Virus 1 (HIV-1) Infection

50mg + 200mg + 25mg

Bictegravir and emtricitabine tablets for HIV-1 infection. Two antiretrovirals work together to stop the virus from copying itself and spreading.

From$64.00/ tabletView

Key points

  • Bictegravir is an integrase inhibitor that blocks HIV from making copies of itself in the body.
  • Biktarvy combines bictegravir with emtricitabine and tenofovir alafenamide in a single tablet.
  • Gilead Sciences is the originator company behind Biktarvy, the three-ingredient combination.

About Biktarvy

Biktarvy is a single-tablet regimen listed under HIV Management for treating HIV-1 infection. Each tablet contains bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg. Gilead Sciences is the originator company behind this three-ingredient combination.

Further reading